From Microdosing to Mystical Experiences with Julianne Keu
Similar Posts
HAVN’s Cluster Headache Treatment BETTER Than Mindmed’s? (HAVN CEO Interview)
HAVN VS. Mindmed – Whose Cluster Headache Treatment Is Better?
Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our “This Week In Psychedelic Stocks” segment.
In light of HAVN’s recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore.
HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.
Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020.
The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms.
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) .
https://havnlife.com/
CSE: HAVN | OTC: HAVLF | FRA: 5NP
#HAVN #HAVNLifeSciences #Mindmed
Welcome to Plant Medicine Week, by Microdose. Join the Psychedelic Revolution
Buy tickets for Plant Medicine Week in Malta, April 5th-8th by using our promo link: https://tickets.plantmedicineweek.com/attendance/event/index/41436/EN?promocodes=PSYC
Get 50% off tickets via the link above or by inputting code PSYC at the checkout over at plantmedicineweek.com/tickets!
Do you both love learning about psychedelics, and need a vacation in beautiful Malta? Well you are in luck, because Microdose.buzz is hosting a one of a kind event next month.
Follow us on Twitter:
@Psy_Invest
@psy_holy
@PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
At the event you will be able to learn about the medical benefits, research, and business of psychedelics, as well as marijuana. The all-star studded line-up includes representatives from companies such as atai Life Sciences (ATAI), Awakn Life Sciences (AWKN, AWKNF) and more.
From panels on psychedelics and sex, to how to make money investing in psychedelics, this event will have it all. Plus…AFTER PARTIES!
No matter if you want to learn about LSD, MDMA, psilocybin, ketamine or more, this event will have it all. We already know that psychedelics can help with mental health, now hear it first hand from the scientists themselves.
#Psychedelics #MentalHealth #Microdose
Interview With Henri Sant-Cassia
In today’s episode of the Psychedelic Spotlight podcast, we spotlight Henri Sant-Cassia, Co-Founding Partner of The Conscious Fund, a leading investment fund in the medicinal psychedelics industry, focused on early stage ventures and psychedelic medicine that are helping to deliver better outcomes for mental health, addiction and pain.
Fungus Among Us: 5 Fascinating Facts About Mushrooms🍄
Join our Newsletter (scroll to the bottom of the page…
Field Trip And Wesana Make Major Moves | FTRP, WESA
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies.
Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics.
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Field Trip Press Release: https://www.globenewswire.com/news-
release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html
Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development
Field Trip Health:
In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities.
Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.
Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.
Wesana:
On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics.
The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division.
Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow.
@psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor
Minimizing Harm and Ensuring Safe Nonclinical Psychedelic Use – Fireside Project
In this captivating episode, David engages in a thought-provoking conversation with none other than Joshua White, the visionary CEO behind the Fireside Project.